Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder

International Clinical Psychopharmacology

Volumn 23, Issue 5, 2008, Pages 291-298

  Cheon, Keun Ah ^a,c   Jun, Jin Yong ^c   Cho, Dae Yeon ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Doo San Engineering Center   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

Author keywords

Attention deficit hyperactivity disorder; Catechol O methyltransferase; Classroom setting; Methylphenidate; Treatment response

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; METHYLPHENIDATE; VALINE; CENTRAL STIMULANT AGENT; DNA;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DRUG DOSE INCREASE; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SCHOOL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA; GENETIC POLYMORPHISM; GENETICS; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CATECHOL O-METHYLTRANSFERASE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DNA; FEMALE; GENOTYPE; HUMANS; MALE; METHYLPHENIDATE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PREFRONTAL CORTEX; TREATMENT OUTCOME;

EID: 54449086933     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328306a977     Document Type: Article

References (45)

1. Arnsten AF, Castellanos FX (2002). Neurobiology of attention regulation and its disorders. In: Martin A, Scahill L, Charney D, Leckman JNY, editors. Textbook of child and adolescent psychopharmacology. New York: Oxford University Press. pp. 99-109.
2. Arnsten AF, Dudley AG (2005). Methylphenidate improves prefrontal cortical cognitive function through a2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 1. doi:10.1186/1744-9081-1-2.
3. Barkley RA (1997). ADHD and the nature of self-control. New York: Guilford Press.
4. Barkley RA, Grodzinsky G, DuPaul GJ (1992). Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report. J Abnorm Child Psych 20:163-188.
5. Barr CL, Wigg K, Malone M, Schachar R, Tannock R, Roberts W, et al. (1999). Linkage study of catechol-O-methyltransferase and attention deficit hyper-activity disorder. Am J Med Genet 88:710-713.
6. Bilder RM, Volavka J, Lachman HM, Grace AA (2004). The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29:1943-1961.
7. Castellanos FX, Tannock R (2002). Neuroscience of attention-deficit/ hyperactivity disorder the search for endophenotypes. Nat Rev Neurosci 3:617-628.
8. Cheon KA, Ryu YH, Kim JW, Cho DY (2005). The homozygosity for 10 repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15:95-101.
9. Cheon KA, Kim BN, Cho SC (2007). Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharmacology 32:1377-1383.
10. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998). ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Press.
11. Eisenberg J, Mei-Tal G, Steinberg A, Tartakovsky E, Zohar A, Gritsenko I, et al. (1999). Haplotype relative risk study of catechol-O- methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive hyperactive phenotype. Am J Med Genet 88:497-502.
12. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. (2005). Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1313-1323.
13. Goldman-Rakic PS (1996). The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Phil Trans R Soc Lond 351:1445-1453.
14. Grossman MH, Emanuel BS, Budaf ML (1992). Chromosomal mapping of the human catechol O-methyltransferase gene to 22q11.1-q11.2. Genomics 12:822-825.
15. Hawi Z, Millar N, Daly G, Fitzgerald M, Gill M (2000). No association between catechol-O-methyltransferase (COMT) gene polymorphism and ADHD in an Irish sample. Am J Med Genet 96:241-243.
16. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. (1997). Schedule for Affective Disorders and Schizophrenia for School Age Children Present and Life Time Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988.
17. Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. (2004). The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version - Korean Version (K-SADS-PL-K). Yonsei Med J 45:81-89.
18. Kirley A, Lowe N, Hawi A, Mullins C, Daly G, Waldman I, et al. (2003). Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet 121:50-54.
19. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski C, Weinshilboum R (1996). Human catechol O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250.
20. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J (1995). Kinetics of human soluble and membrane-bound catechol O methyltransfer-ase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-4210.
21. McGough JJ (2005). Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 57:1367-1373.
22. Manor I, Kotler M, Sever Y, Eisenberg J, Cohen H, Ebstein RP, et al. (2000). Failure to replicate an association between the catechol-O-methyltransferase polymorphism and attention deficit hyperactivity disorder in a second, independently recruited Israeli cohort. Am J Med Genet 96:858-860.
23. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF (2003). Catechol O-methyltransferase val1 58 met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci 100:6186-6191.
24. McInnes A, Bedard A-C, Hogg-Johnson S, Tannock R (2007). Preliminary evidence of beneficial effects of methylphenidate on listening comprehension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17:35-49.
25. Mehta AD, Ulbert I, Schroeder CE (2000). Intermodal selective attention in monkeys. I: distribution and timing of effects across visual areas. Cerebr Cortex 10:343-358.
26. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002). Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22:389-395.
27. Napolitano A, Cesura AM, Da Prada M (1995). The role of monoamine oxidase and catechol-O-methyltransferase in dopaminergic neurotransmission. J Neural Transm 45:35-45.
28. Norton N, Kirov G, Zammit S, Jones G, Jones S, Owen R, et al. (2002). Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. Am J Med Genet 114:491-496.
29. Payton A, Holmes J, Barrett JH, Hever T, Fitzpatrick H, Trumper AL, et al. (2001). Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder: a family-based study. Am J Med Genet 105:464-470.
30. Qian Q, Wang Y, Zhou R, Li J, Wang B, Glatt S, et al. (2003). Family-based and case-control association studies of catechol-O- methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual polymorphism. Am J Med Genet 118B:103-109.
31. Risch NJ (2000). Searching for genetic determinants in the new millennium. Nature 405:847-856.
32. Robbins TW (1996). Dissociating executive functions of the prefrontal cortex. Phil Trans R Soc Lond 351:1463-1471.
33. Roman T, Szobot C, Martine S, Biederman J, Rohde LA, Hutz MH (2002). Dopamine transporter gene and response to methylphenidate in attention deficit/hyperactivity disorder. Pharmacogenetics 12:497-499.
34. Sagvolden T, Johansen EB, Aase H, Russell VA (2005). A dynamic developmental theory of attention deficit hyperactivity disorder (ADHD) predominantly hyperactive/impulsive subtype. Behav Brain Sci 28:397-468.
35. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1-57.
36. So YK, Noh JS, Kim YS, Ko SG, Koh YJ (2002). The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc 41:283-289.
37. Sonuga-Barke EJS (2003). The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 27: 593-604.
38. Stoner G, Carey S, Ikeda M, Shinn M (1994). The utility of curriculum-based measurement for evaluating the effects of methylphenidate on academic performance. J Appl Behav Anal 27:101-113.
39. Stuss DT, Knight RT (2002). Principles of frontal lobe function. New York: Oxford University Press. 616p.
40. Tahir E, Curran S, Yazgan Y, Ozbay F, Cirakoglu B, Asherson P (2000). No association between low and high activity catecholamine-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry 5:396-404.
41. Tripp G, Schaughency EA, Clarke B (2006). Parent and teacher rating scales in the evaluation of attention-deficit hyperactivity disorder: contribution to diagnosis and differential diagnosis in clinically referred children. J Dev Behav Pediatr 27:209-218.
42. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, Gabrieli JDE (1998). Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Nat Acad Sci U S A 95:14494-14499.
43. Winsberg BG, Comings DE (1999). Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38:1474-1477.
44. Weinshilboum RM, Otterness DM, Szumlanski CL (1999). Methylation pharma-cogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19-52.
45. Xing C, Torres-Caban M, Wang T, Lu Q, Xing G, Elston RC (2007). Linkage studies of catechol-O-methyltransferase (COMT) and dopamine-beta- hydroxylase (DBH) cDNA expression levels. Biomed Chromatogr Proc 1 (Suppl 1):S95.